Stifel maintains Buy rating on Glaukos stock ahead of Epioxa PDUFA date
PositiveFinancial Markets

Stifel has reaffirmed its Buy rating on Glaukos stock as the company approaches the PDUFA date for Epioxa, a significant milestone that could enhance its market position. This endorsement reflects confidence in Glaukos' potential to deliver innovative solutions in the ophthalmic space, which is crucial for investors looking for growth opportunities in the healthcare sector.
— Curated by the World Pulse Now AI Editorial System